New indication approved for asthma drug

Article

Merck received FDA approval for a new indication for montelukast 10 mg (Singulair). The medication can now be prescribed for exercise-induced bronchoconstriction (EIB) in patients 15 years and older [more].

Merck received FDA approval for a new indication for montelukast 10 mg (Singulair). The medication can now be prescribed for exercise-induced bronchoconstriction (EIB) in patients 15 years and older [more].

According to the manufacturer, a single dose prevented EIB when taken two hours before exercise. Some patients benefited from the drug at 8.5 and 24 hours after administration, however some did not. Symptoms include shortness of breath, cough, wheeze, and chest tightness brought on by exercise. EIB affects a broad spectrum of patients with asthma.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.